European Commission Approves Pembrolizumab and Sacituzumab Govitecan Combination for Frontline mTNBC
The European Commission’s (EC) approval of sacituzumab govitecan plus pembrolizumab for PD-L1-positive metastatic triple-negative breast cancer (mTNBC) hinges on findings from the…